Report Highlights
The global market for antifungal therapeutics was valued at $10.7 billion in 2011 and is projected to reach $12.2 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.7%.
SCOPE OF REPORT
This study examines human applications both marketed and in the development of antifungal technologies. In an extensive analysis, BCC examines each market segment, presents its current market status, and presents various forecasts for growth over the next five years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance, and changes in consumerism such as a greater demand for OTC medications and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2010 to 2011, with estimates for 2016, including CAGR as a percentage.
Analyst Credentials
Mary Anne Crandall is a medical research analyst and has specialized in the pharmaceuticals and medical device industry for the last 25 years. She has completed several in-depth studies on various medical topics requiring both expertise and knowledge of the industry. She is a retired nurse, has a B.S. and an M.S. in Psychology and is currently working on her Ph.D.
Report Highlights
-
The global market for human antifungal therapeutics was valued at $9.8 billion in 2009 and is expected to increase at a compound annual growth rate (CAGR) of approximately 3.8% to reach $11.3 billion in 2014.
-
The Latin and South American region will experience the greatest compound annual growth rate (CAGR) of 8.3%, reflecting an increase in revenues from $637 million in 2009 to $949 million in 2014.
-
In North America, human antifungal therapeutics were valued at $3.9 billion in 2009 and are expected to increase at a 0.7% compound annual growth rate (CAGR) to reach $4 billion in 2014.
Report Highlights
-
The total global market for antifungal agents was worth more than $13.5 billion in 2005 and declined to just under $12.2 billion in 2006. The market will continue to dip through 2007 to $11.9 billion but will recover to more than $14.7 billion, a compound annual growth rate (CAGR) of 2.8%
-
Antifungal agents for humans held the highest share of the market through the forecast period. In 2007 they will be worth more than $11.2 billion and will reach nearly $14 billion by 2012, a CAGR of 4.5%.
-
Trends for fungal infections among animals are still a major concern as industry trends indicate. The market for animal antifungals will be worth $107 million in 2007 and will reach $110.7 million by 2012, a CAGR of 3.5%.
Report Highlights
-
The market for antifungal drugs is estimated at $5.9 billion in 2002, including both prescription and OTC products.
-
Overall, the market is projected to rise at an average annual growth rate (AAGR) of 7.9% through 2007 to $8.7 billion.
-
There are about 30 branded prescription systemic and topical antifungal agents on the market and several dozen over-the-counter branded and generic topical antifungal products.
-
Products from several entirely new categories of compounds will be introduced during the forecast period.
-
More than a dozen new prescription products are in clinical development and will contribute to the growth in this market.
Related Reports
Markets for Advanced Wound Care Technologies
The total market for advanced wound care reached at $3.4 billion in 2010. It is expected to reach at $3.6 billion in 2011; it will further grow to $4.6 billion by 2016 at a compound annual growth rate (CAGR) of 4.9%.
Recent Reports
Over-the-Counter (OTC) Drugs, and Vitamins & Dietary Supplements: Global Markets
The global market for over-the- counter (OTC) drugs, vitamins and dietary supplements is expected to grow from $276.9 billion in 2025 and is projected to reach $371.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2025 to 2030.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.
The Global Influenza Market
The global influenza market is expected to grow from $9.0 billion in 2024 and is projected to reach $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.
Liver Disease Treatments: The Global Market
The global market for liver disease treatments is estimated to increase from $46.0 billion in 2024 to reach $69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.
Cancer Immunotherapy: Technologies and Global Markets
The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.
Top Trending Reports
Global Markets for Emerging Medical Device Technologies
The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.
Global Diabetic Care Devices Market
The global market for diabetes monitoring devices is expected to grow from $16.6 billion in 2024 to $26.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.1% from 2024 through 2029.
Single-Cell Genomics and Proteomics: Emerging Technologies and Markets
The global market for single-cell genomics and proteomics is expected to grow from $4.0 billion in 2024 to reach $9.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 17.6% from 2024 through 2029.
Global Lithium-ion Battery Market
The global market for lithium-ion battery (LIB) is expected to grow from $117.8 billion in 2024 and is projected to reach $221.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.5% during the forecast period of 2024 to 2029.
2024 Medical Devices Research Review
The medical device industry is a multi-billion-dollar industry whose outlook is supposed to rise in the coming years These devices treat and diagnose a multitude of patient conditions and work much better than drugs.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More